420 with CNW — FDA Passes the Buck, Gives Congress Plenty to Consider About CBD Marketing
The current tense situation regarding CBD-containing products will be maintained for the time being as a result of the U.S. Food and Drug Administration’s recent announcement that it will not regulate those products, instead delegating that responsibility to Congress. This adds to the workload for a Congress that is already becoming more acrimonious and creates more uncertainty for businesses considering entering the $4 billion-plus CBD market. Congress must make decisions regarding intoxicating cannabinoids derived from hemp, such as delta-10 THC and delta-8, in addition to tackling broader cannabis policy reform, which includes banking access, tax relief and the issue of…

















